Multiple Sclerosis

Detection of antibodies could identify patients who do not respond well to interferon beta

Published in Health and Medicine Week, October 27th, 2003

Danish research highlights how the detection of antibodies to interferon beta - the first-choice treatment for multiple sclerosis patients - could be important in identifying patients who do not respond well to interferon beta, with implications for the provision of alternative drug therapy.

Interferon beta is the first-line treatment for relapsing-remitting multiple sclerosis, but the drug can induce neutralizing antibodies against itself, which might reduce its effectiveness.

Per Soelberg Sorensen from Copenhagen University Hospital, Denmark, and colleagues measured neutralizing antibodies every year for up to 5 years among 541 patients with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health and Medicine Week

Source: Health and Medicine Week (2003-10-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry